FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* LOSCALZO JOSEPH				2	2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [LPTX]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
LOSCALZO JOSEPH													V Director	r		10% Ow	ner
(Last)	`	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/23/2017							Officer (give title Other below) below				pecify	
C/O LEAP THERAPEUTICS, INC.																	
47 THORNDIKE STREET SUITE B1-1					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	IDGE M	IA	02141									- 1	X Form fi	led by One		Ü	
———	IDGE W		02141										Form fi Person	led by More	than O	ne Reporti	ng
(City)	(S	State)	(Zip)														
		Та	ble I - Non-l	Derivat	ive Se	ecuritie	s A	cquired, C	Dispos	sed	of, or Be	neficiall	y Owned				
Date				. Transact Pate Month/Day	Execution Date,		Code (In	Transaction Disposed Of (D) (Instr. 3, 4)			5. Amour Securitie Beneficia Owned F	s Illy ollowing	6. Owne Form: D (D) or Ir (I) (Instr	Direct Ir ndirect B r. 4) C	7. Nature of Indirect Beneficial Ownership		
				Code			V An	nount	(A) (D)	Price	Reported Transacti (Instr. 3 a	action(s)		((Instr. 4)		
			Table II - De (e					quired, Dis s, options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code (Instr.		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		and	7. Title and Amount of Securities Underlying Derivati Security (Instr. 3 an 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y C	Do. Dwnership Form: Direct (D) or Indirect I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expira Date	ition	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$9.9	01/23/2017		A		11,000		(1)	01/22/	2027	Common Stock, \$0.001 par value per share	11,000(1)	\$0	11,000		D	
Stock Option (Right to Buy)	\$9.9	01/23/2017		A		15,000		(2)	01/22/	2027	Common Stock, \$0.001 par value per share	15,000 ⁽²⁾	\$0	15,000		D	

Explanation of Responses:

- 1. The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and shall vest and is fully vested as of the grant date.
- 2. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 23, 2017, the Vesting Start Date.

/s/ Douglas E. Onsi as attorneyin-fact for Joseph Loscalzo 01/2

01/23/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.